Ketoprofen (2-(3-benzoylphenyl)-propionic acid), belongs to the family of 2-arylpropionic acids (profens), is one of the nonstreroidal anti-inflammatory drugs. The production of single enantiomer of ketoprofen is expected to grow due to its enantiomer displaying better pharmacologic activities and benefits. Kinetic resolution is the most widely used method in the production of enantiomer pure ketoprofen. However, the process has a number of limitations, which are yet to be overcome. These limitations call for an innovative approach where two processes (enantioselective esterification and dynamic kinetic resolution) can be combined and operated under a single operating enzymatic membrane reactor system. The technology is more economical, more enantiomerically benign and has a potential maximum yield more than 50%. This paper will highlight the current technology in the production of biologically active (S)-ketoprofen, the limitations associated with the production and solutions to overcome these limitations. (c) 2005 Elsevier Ltd. All rights reserved.